SEC Form 3 · accession 0001615774-19-000107
Intec Pharma Ltd. · NTEC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 2, 2019 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001638381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | holding | — | — | — | 51,761 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.526 | holding | — | — | — | — | May 15, 2026 | Ordinary Shares | 224,478 | — | D |
Explanation of responses
- F1The stock option vested and became exercisable as to one-third of the total shares on July 1, 2017 and one-third of the total shares on July 1, 2018. The remaining shares subject to the stock option vest and become exercisable on July 1, 2019.
Remarks
The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.